Trials / Unknown
UnknownNCT04452929
The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- Danish Headache Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
A randomized, double-blind, placebo-controlled, parallel study to investigate the effect of erenumab in calcitonin-gene related peptide and cilostazol experimental models of migraine in humans. Followed by a 6-month open-label extension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erenumab | Subcutaneous injection of 140 mg erenumab. |
| DRUG | Placebo | Subcutaneous injection of saline placebo. |
| DRUG | Calcitonin gene-related peptide | Intravenous infusion of 1.5ug/min calcitonin gene-related peptide over 20 minutes. |
| DRUG | Cilostazol | Oral intake of 200 mg cilostazol. |
Timeline
- Start date
- 2020-07-22
- Primary completion
- 2022-02-01
- Completion
- 2022-07-01
- First posted
- 2020-07-01
- Last updated
- 2020-10-08
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT04452929. Inclusion in this directory is not an endorsement.